| Programmed death ligand-1 expression in non-small cell lung cancer V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ... Laboratory investigation 94 (1), 107-116, 2014 | 871 | 2014 |
| Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer J McLaughlin, G Han, KA Schalper, D Carvajal-Hausdorf, V Pelekanou, ... JAMA oncology 2 (1), 46-54, 2016 | 778 | 2016 |
| Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology K Bera, KA Schalper, DL Rimm, V Velcheti, A Madabhushi Nature reviews Clinical oncology 16 (11), 703-715, 2019 | 720 | 2019 |
| Sotorasib for Lung Cancers with KRAS p.G12C Mutation F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ... New England Journal of Medicine 384 (25), 2371-2381, 2021 | 676 | 2021 |
| In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasPD-L1 mRNA Positivity and Outcome in Breast Cancer KA Schalper, V Velcheti, D Carvajal, H Wimberly, J Brown, L Pusztai, ... Clinical cancer research 20 (10), 2773-2782, 2014 | 494 | 2014 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 486 | 2020 |
| Radiomics and radiogenomics in lung cancer: a review for the clinician R Thawani, M McLane, N Beig, S Ghose, P Prasanna, V Velcheti, ... Lung cancer 115, 34-41, 2018 | 381 | 2018 |
| Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials M Khunger, S Rakshit, V Pasupuleti, AV Hernandez, P Mazzone, ... Chest 152 (2), 271-281, 2017 | 376 | 2017 |
| Objective measurement and clinical significance of TILs in non–small cell lung cancer KA Schalper, J Brown, D Carvajal-Hausdorf, J McLaughlin, V Velcheti, ... Journal of the National Cancer Institute 107 (3), dju435, 2015 | 368 | 2015 |
| ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial JM Wrangle, V Velcheti, MR Patel, E Garrett-Mayer, EG Hill, JG Ravenel, ... The Lancet Oncology 19 (5), 694-704, 2018 | 314 | 2018 |
| Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403, 2017 | 301 | 2017 |
| Selective RET kinase inhibition for patients with RET-altered cancers V Subbiah, V Velcheti, BB Tuch, K Ebata, NL Busaidy, ME Cabanillas, ... Annals of Oncology 29 (8), 1869-1876, 2018 | 297 | 2018 |
| Perinodular and intranodular radiomic features on lung CT images distinguish adenocarcinomas from granulomas N Beig, M Khorrami, M Alilou, P Prasanna, N Braman, M Orooji, S Rakshit, ... Radiology 290 (3), 783-792, 2019 | 226 | 2019 |
| Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell AnalysisPD-1, LAG-3 … I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ... Clinical Cancer Research 25 (15), 4663-4673, 2019 | 199 | 2019 |
| Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma M Vassilakopoulou, M Avgeris, V Velcheti, V Kotoula, T Rampias, ... Clinical Cancer Research 22 (3), 704-713, 2016 | 189 | 2016 |
| Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity C Calabrese, E Kirchner, A Kontzias, V Velcheti, LH Calabrese RMD open 3 (1), e000412, 2017 | 180 | 2017 |
| Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non–small cell lung cancer G Corredor, X Wang, Y Zhou, C Lu, P Fu, K Syrigos, DL Rimm, M Yang, ... Clinical cancer research 25 (5), 1526-1534, 2019 | 179 | 2019 |
| Clinical characteristics and outcomes of COVID-19–infected cancer patients: a systematic review and meta-analysis H Zhang, H Han, T He, KE Labbe, AV Hernandez, H Chen, V Velcheti, ... JNCI: Journal of the National Cancer Institute 113 (4), 371-380, 2021 | 172 | 2021 |
| Rational design of anti-GITR-based combination immunotherapy R Zappasodi, C Sirard, Y Li, S Budhu, M Abu-Akeel, C Liu, X Yang, ... Nature medicine 25 (5), 759-766, 2019 | 169 | 2019 |
| Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerPD-L1, IDO-1, and B7-H4 in NSCLC KA Schalper, D Carvajal-Hausdorf, J McLaughlin, M Altan, V Velcheti, ... Clinical Cancer Research 23 (2), 370-378, 2017 | 167 | 2017 |
Anant MadabhushiDepartment of Biomedical Engineering, Professor, Biomedical Engineering, Emory Univ & Georgia TechGeverifieerd e-mailadres voor emory.edu
